Search

Copyright of Namık Kemal Tıp Dergisi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVES: To elucidate prognostic factors, determine the best course of treatment methods, and assess oncological results in individuals diagnosed with uterine sarcoma. STUDY DESIGN: Between January 2001 and August 2023, 30 patients with uterine sarcomas (US) were included and analyzed in this cross-sectional study. Sixteen patients (53.3%) had uterine leiomyosarcoma, 6 patients (20%) had high-grade endometrial stromal sarcoma, 8 patients (26.7%) had low-grade endometrial stromal sarcoma. RESULTS: The median follow-up of all participants was 50 months. Recurrence was detected in 43.3% of the patients. 5-year survival ratio was 73.3%, 5-year disease-free survival ratio was 66.7%, the overall survival ratio was 70% and the overall disease-free survival rate was 56.6%. No difference was observed between groups in terms of survival comparisons. No statistically significant effect of adjuvant systemic chemotherapy, adjuvant radiotherapy, and combined treatments on median overall survival and median disease-free survival was detected (p>0.05). CONCLUSION: Uterine sarcomas are uncommon malignancies characterized by a poor prognosis, even in early stages, and they are associated with a high recurrence ratio. The most effective treatment method remains unclear to date. [ABSTRACT FROM AUTHOR]

Objectives: We aimed to evaluate the relation of the pre-treatment hemoglobin-albumin-lymphocyte-platelet (HALP) score with survival and prognosis of locally advanced esophageal squamous cell carcinoma (ESCC) patients receiving chemoradiotherapy (CRT). Methods: We retrospectively included 45 patients with esophageal squamous cell carcinoma who were treated with chemoradiotherapy. The HALP score was calculated as hemoglobin level (g/L)*albumin level (g/L)*lymphocyte count (/L)/platelet count(/L). Results: According to the receiver operating characteristic (ROC) curve, the median of the HALP score was 42.36. According to this value, the patients were divided into two groups; Group 1 included 28 patients who had a HALP score <42.36 and Group 2 included 17 patients who had a HALP score >42.36. Median OS was 20.5 months in Group 1 and the median OS was not reached in Group 2 (p=0.033). Median PFS in all patient groups was 15.2 months. The median PFS was 12.2 months in Group 1 and 30.9 months in Group 2 (p=0.127). Univariate Cox regression analysis showed that pre-treatment low levels of HALP were associated with a short median time of OS (p=0.042). Conclusion: Our study suggested that pretreatment low HALP score was associated with poor OS in patients with locally advanced ESCC who were treated with CRT. [ABSTRACT FROM AUTHOR]

OBJECTIVE: We compared the survival outcomes of surgery within multimodality treatment regimens with the outcomes of definitive chemoradiation treatments in patients diagnosed with clinical (c) IIIB/N2 non-small cell lung cancer (NSCLC). We investigated whether surgery within multimodality treatment provides a survival advantage at this stage. MATERIAL AND METHODS: Data from 79 patients with cIIIB/N2 between 2009 and 2016 were analyzed retrospectively. While the surgery was performed after neoadjuvant therapy in 51 cases (IIIB/Surgery Group), definitive chemotherapy ± radiotherapy was applied in 28 cases (IIIB/Definitive Group). RESULTS: In cIIIB/N2 cases, the 5-year overall survival (OS) was 27.4%, with a median OS of 24.6 months. The 5-year OS of the IIIB/ Surgery Group was 27.3% (median survival 22.5 months), while it was 28.6% (median survival 29.1 months) in the IIIB/Definitive Group (P = .387, HR = 0.798, 95% CI, 0.485-1.313). Although there was a survival advantage in the group with a pathological complete response (PCR) after surgery (n = 14) compared to the group that did not (n = 37), the observed difference was not statistically significant. (5-year OS; 42.9% vs. 18.5%, P = .104). Additionally, there was no statistically significant difference between the survival of PCR patients and the IIIB/Definitive Group in terms of OS (P = .488). CONCLUSION: Surgery performed within multimodality treatment regimens in selected cIIIB/N2 cases did not provide a survival advantage over definitive chemoradiation treatments. [ABSTRACT FROM AUTHOR]

Objectives: More than half of gastric cancer patients have no chance of resection at the time of diagnosis. In gastric cancer, which has increased frequency with age, chemotherapy efficacy and tolerability in metastatic gastric cancer aged 75 and over have been investigated due to the fact that the elderly patient population is not sufficiently involved in the studies. Methods: In our study, the clinical and demographic characteristics of patients, treatment regimens and responses, prognostic factors, grad 3-4 toxicity, progression-free survival (PFS) and overall survival (OS) were examined. Results: In the study involving 118 patients, PFS was 5.8 months and OS was 8.4 months. A disease control rate of 38.1% was achieved with chemotherapy. Conclusion: Since the OS in this study was 10.5 months in patients with ECOG PS 0-1, 13.8 months in patients who received two lines or more, and the frequency of side effects was acceptable, we believe that this patient population should not be left untreated. Since there are acceptable survival values even with single-agent therapies, monotherapy can be recommended for patients with poor ECOG PS and combination therapies can be recommended for patients with good PS without comorbidities. [ABSTRACT FROM AUTHOR]

Background: Cancer is a significant health problem for refugees and host countries. Breast cancer is the most common cancer among refugees. The subject of our study is to examine the clinical and pathological features of Syrian refugees with breast cancer and compare them with Turkish patients with breast cancer. Methods: Data of patients with breast cancer between January 2018 and December 2020 were retrospectively reviewed. The clinical and histological features, treatment modalities and overall survival were collected and analyzed. Results: A total number of 338 women with breast cancer were included in this study. Ninety-nine of the 338 (29.3%) patients were Syrian refugees and 239 patients (70.7%) were Turkish. The median follow-up time was significantly lower in Syrian patients (P < 0.001). Median OS was 146 months in Turkish and 116 months in Syrian group (P = 0.022). Independent risk factors associated with long survival were receiving adjuvant chemotherapy (HR 0.465; 95% CI 0.234-0.926; P = 0.029), adjuvant radiotherapy (HR 0.372 95% CI 0.182-0.758; P = 0.007), and adjuvant hormonotherapy (HR 0.367; 95% CI 0.201-0.669; P = 0.001). The rates of receiving adjuvant chemotherapy, adjuvant radiotherapy, and adjuvant hormonal therapy were significantly lower in the Syrian group (P = 0.023, P = 0.005, P = 0.002, respectively). Conclusion: Syrian refugees with breast cancer are more likely to receive suboptimal treatments. They have inferior survival compared to local patients. Our findings highlight the need for the provision of cancer therapy in such vulnerable populations. We suggest that more attention should be paid to breast cancer, as it is the most common cancer among refugees. [ABSTRACT FROM AUTHOR]